Sugi Predict

Sugi Predict / Compounds / SCHEMBL5624968

SCHEMBL5624968

SCHEMBL5624968

CC1=Nc2ccc(S(=O)(=O)N(C)C)cc2S(=O)(=O)N1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 1/20 0.38
▸ HTR2B P41595 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ GLO1 Q04760 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ MAPT P10636 2/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ ALDH1A1 P00352 6/20 0.35
▸ HTT P42858 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ POLB P06746 2/20 0.35
▸ VCAM1 P19320 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10945057 0.85 VCAM1 (0.40) HTR2CHTR2BCA12CA1CA2
SCHEMBL5625166 0.83 CA1 (0.56) CA12CA1CA2CA7GLO1
SCHEMBL5628842 0.82 HDAC4 (0.36) HTR2CHTR2BCA12CA1CA2
SCHEMBL12570063 0.76 CA2 (0.47) CA12CA1CA2CA7CA9
SCHEMBL10909630 0.75 CA12 (0.66) HTR2CHTR2BCA12CA1CA2
SCHEMBL16455556 0.73 CA12 (0.51) CA12CA1CA2CA7GLO1
Diazoxide SCHEMBL41254 0.73 CHEK1 (0.51) CA12CA1CA2CA7CA9
Diazoxide SCHEMBL1726275 0.72 CHEK1 (0.50) CA12CA1CA2CA7CA9
Diazoxide SCHEMBL1725516 0.72 CHEK1 (0.50) CA12CA1CA2CA7CA9
Diazoxide SCHEMBL1725216 0.72 CHEK1 (0.50) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 — — US claimed
EP-1071426-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2001-01-31 — — EP claimed
WO-1999042456-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 1999-08-26 — — WO claimed
US-7235548-B2 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2007-06-26 — — US disclosed
US-6943159-B1 Compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S (DK) 2005-09-13 — — US disclosed
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators NEUROSEARCH A/S. 2004-03-04 — — US disclosed
EP-1071426-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2001-01-31 — — EP disclosed
WO-1999042456-A2 NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 1999-08-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043987-A1 Novel compounds and their use as positive AMPA receptor modulators GRIK4, GRIA4, GRM2 HTR2C 564/4885HTR2B 529/4885CA12 1624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.